Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent β-Thalassemia with Chronic Anemia
2018-001984-21Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Aug 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of rusfertide in beta thalassemia and anaemia (2 cohorts), sponsored by Protagonist Therapeutics, Inc. Primary endpoints: Safety and tolerability of PTG-300 and Pharmacokinetics of PTG-300. Started Aug 2018; status: completed.
02
Drugs
rusfertide
03
Conditions
beta thalassemiaanaemia
Beyond the preview
Go deeper on 2018-001984-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001984-21.